We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 264

Top 10 differences in patent litigation in Canada and the U.S.
  • Gowling WLG
  • USA, Canada
  • January 24 2018

Patent owners are increasingly looking outside the United States in order to enforce their patent rights. Many would argue that the Inter Partes


Canadian patent law: 2017 year in review
  • Gowling WLG
  • Canada
  • January 3 2018

2017 was a busy year in Canadian patent law. The contentious Promise Doctrine was rejected by the Supreme Court of Canada in AstraZeneca v Apotex


Actavis v Eli Lilly
  • Gowling WLG
  • United Kingdom, Canada, European Union
  • November 27 2017

Following the Supreme Court's decision in Actavis v Lilly, is there a gap between the interpretation of a patent claim for validity purposes and its


Singapore High Court has no original jurisdiction to revoke a patent
  • Gowling WLG
  • Singapore, United Kingdom
  • October 23 2017

For years, defendants in patent infringement proceedings have brought counterclaims for revocation of the patent. However, a recent High Court


Defects in pre-patent issue process do not render a patent void
  • Gowling WLG
  • Canada
  • October 18 2017

In Apotex Inc. v Pfizer Inc. et al, 2017 FCA 201, the Federal Court of Appeal refused to void a patent based on an administrative error made during


Dealing with copyright and trademark infringement online
  • Gowling WLG
  • Global
  • October 18 2017

Online infringement takes many forms, from the sale of counterfeit or infringing products via the internet, to copying another business' website. In


Actavis v Eli Lilly: the doctrine of equivalents in the UK, France and Germany
  • Gowling WLG
  • United Kingdom, European Union
  • October 4 2017

In view of the UK Supreme Court's judgment in Actavis v Eli Lilly, when will an 'equivalent' infringe as an immaterial variant? How does this compare


Actavis v Eli Lilly - what is "normal interpretation"?
  • Gowling WLG
  • United Kingdom, European Union
  • September 26 2017

In a landmark decision (Actavis v Eli Lilly), the UK Supreme Court has re-steered the law of patent infringement in the UK, stating that there is a


Curtain lifted on proposed amended PM(NOC) Regulations
  • Gowling WLG
  • Canada
  • July 17 2017

The curtain has been lifted to reveal the proposed amendments to the Patented Medicines (Notice of Compliance) Regulations (the “Amended


UK Supreme Court introduces doctrine of equivalents in patent law in Actavis v Lilly
  • Gowling WLG
  • United Kingdom, European Union
  • July 13 2017

In a landmark decision (Actavis v Eli Lilly), the UK Supreme Court has re-steered the law of patent infringement in the UK, stating that there is a